Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

VU 0155041

Known as: VU-0155041, VU0155041 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
In the present study, we investigated the effect of ACPT-I [(1S, 3R,4S)-1-aminocyclopentane-1,2,4-tricarboxylic acid], a blood… Expand
  • table 1
  • table 2
  • table 3
  • table 4
  • figure 1
2015
2015
Type 4 metabotropic glutamate (mGlu4) receptors are emerging targets for the treatment of various disorders. Accordingly… Expand
2015
2015
Promoting both endogenous and exogenous neural stem cells' (NSCs) survival in the hostile host environments is essential to cell… Expand
2013
2013
Group III metabotropic glutamate receptors (mGluR4,7,8) are widely distributed in the basal ganglia. Injection of group III mGluR… Expand
2012
2012
BACKGROUND AND PURPOSE We recently reported that broad spectrum agonist‐induced activation of presynaptic group III metabotropic… Expand
2012
2012
The present study was designed to evaluate the possible neuroprotective effects of metabotropic glutamate receptor (mGluR7… Expand
2012
2012
Glutamate, the major excitatory neurotransmitter in the retina, functions by activation of both ionotropic (iGluR) and… Expand
2011
2011
Glutamate receptors (GluRs) play a critical role in pain pathway. Recent studies have shown that activation of spinal group III… Expand
2009
2009
This Letter describes the synthesis and SAR of the novel positive allosteric modulator, VU0155041, a compound that has shown in… Expand
  • figure 1
  • table 1
  • table 2
  • table 3
  • figure 2
Highly Cited
2008
Highly Cited
2008
Parkinson's disease (PD) is caused by the death of dopamine neurons in the basal ganglia and results in motor symptoms such as… Expand
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • figure 4